Yes, lumateperone, marketed under the brand name Caplyta, is FDA approved. The U.S. Food and Drug Administration (FDA) approved Caplyta on December 20, 2019, for the treatment of schizophrenia in adults. Additionally, on December 17, 2021, the FDA approved lumateperone for the treatment of bipolar depression, both as monotherapy and as adjunctive therapy with lithium or valproate .
Lumateperone is an atypical antipsychotic used to treat schizophrenia in adults. It is also used to treat depressive episodes associated with bipolar I or II disorder, either alone or in combination with lithium or valproate. Lumateperone functions by modulating the activity of neurotransmitters in the brain, which helps in managing symptoms of these mental health conditions.
Lumateperone is available in oral capsule form with dosages of 10.5 mg, 21 mg, and 42 mg. The typical dosage for both schizophrenia and bipolar depression is 42 mg taken once daily, with or without food.
Common side effects of lumateperone include:
Serious side effects may include:
It's important to monitor for signs of allergic reactions and sudden changes in mood or behavior, especially in young adults or individuals with a history of depression or mental illness.
Lumateperone can interact with various medications, including antibiotics, antifungals, antivirals, blood pressure medications, asthma medications, and others. It's crucial to inform your doctor about all the medications and supplements you are currently taking to avoid potential interactions.
Lumateperone, under the brand name Caplyta, is FDA approved for the treatment of schizophrenia and bipolar depression in adults. Its approval on December 20, 2019, and subsequent expansion for bipolar depression treatment on December 17, 2021, mark significant advancements in the management of these conditions.
In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!